Company news
Resverlogix Corp. news in 2023
Resverlogix Corp.'s news releases, calls and decks from 2023, newest first.
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
October 4, 2023
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
August 29, 2023
Resverlogix Announces Warrant Repricing and One-Year Extension
June 29, 2023
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
June 20, 2023
Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
June 12, 2023
Resverlogix Announces One-Year Extension of Debenture
March 20, 2023
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
March 2, 2023